What are the indications, dosing regimen, contraindications, and monitoring recommendations for the selective SGLT1 inhibitor sotagliflozin (dual SGLT1/2 inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SGLT1 Inhibitor Detail: Sotagliflozin

Sotagliflozin is a dual SGLT1/SGLT2 inhibitor approved for reducing cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with type 2 diabetes and chronic kidney disease, as well as in patients with heart failure regardless of diabetes status or ejection fraction. 1, 2

Mechanism of Action

Sotagliflozin uniquely inhibits both SGLT2 (primarily in the kidneys) and SGLT1 (primarily in the intestines), providing dual mechanisms of glucose reduction 3, 4:

  • SGLT2 inhibition: Increases urinary glucose excretion by blocking renal glucose reabsorption 3
  • SGLT1 inhibition: Delays intestinal glucose absorption, reducing postprandial glucose excursions and increasing GLP-1 secretion 4

This dual mechanism differentiates sotagliflozin from selective SGLT2 inhibitors by providing additional postprandial glucose control 4.

FDA-Approved Indications

Primary cardiovascular indication 2:

  • Reduce risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with:
    • Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors
    • Heart failure (regardless of diabetes status or ejection fraction)

European indication (not FDA-approved in US for this use) 1:

  • Adjunct to insulin in adults with type 1 diabetes and BMI ≥27 kg/m² who have failed to achieve adequate glycemic control despite optimal insulin therapy

Dosing Regimen

Standard dosing 1, 5:

  • Initial dose: 200 mg orally once daily
  • Titration: May increase to 400 mg once daily if tolerated, typically within the first 6 months
  • Timing: Can be taken at any time of day, with or without food

Dose-response considerations 5, 6:

  • The 400 mg/day dose provides greater improvement in most glycemic and non-glycemic outcomes compared to 200 mg/day without increasing adverse event risk 5
  • Benefits tend to be greater in patients with BMI ≥27 kg/m² 6

Renal Dose Adjustments

Initiation criteria 2:

  • Can be initiated in patients with eGFR ≥25 mL/min/1.73 m²

Continuation with declining renal function 7:

  • Continue sotagliflozin even when eGFR falls below 20 mL/min/1.73 m² until dialysis or transplantation 7
  • Evidence from CREDENCE trial supports persistent cardiovascular and kidney benefits with continuation at eGFR <20 mL/min/1.73 m² 7

Important caveat: Glycemic benefits are reduced at eGFR <45 mL/min/1.73 m², similar to selective SGLT2 inhibitors 8

Contraindications

Absolute contraindications 1, 2:

  • Active dialysis
  • History of serious hypersensitivity reaction to sotagliflozin
  • Type 1 diabetes with history of diabetic ketoacidosis (for heart failure indication, as these patients were excluded from trials) 8

Relative contraindications requiring careful consideration 9:

  • Pregnancy or breastfeeding (class effect with SGLT2 inhibitors) 9
  • Severe renal impairment on dialysis 9

Precautions and Risk Mitigation

Diabetic ketoacidosis (DKA) risk - CRITICAL 5, 2:

  • Sotagliflozin carries an eightfold increased risk of DKA compared to placebo in type 1 diabetes 8
  • Risk factors for DKA include higher baseline HbA1c and inadequate basal insulin dose adjustment 5
  • Mitigation strategy: Down-titrate basal insulin dose by approximately 20% when initiating therapy in patients on insulin 9
  • Discontinue at least 3 days before planned surgery to prevent postoperative ketoacidosis 9

Volume depletion 9:

  • May contribute to intravascular volume contraction
  • Consider stopping or reducing diuretic dose when initiating therapy 9
  • Risk of volume depletion events increased (RR 2.19) 5

Hypoglycemia management 9:

  • If HbA1c is well-controlled at baseline or patient has history of frequent hypoglycemic events, wean or stop sulfonylurea or glinide 9
  • Paradoxically, sotagliflozin reduces overall hypoglycemia events (-9.09 events per patient-year) and severe hypoglycemia (RR 0.69) 5

Genital and urinary tract infections 9, 5:

  • Increased risk of genital tract infections (RR 3.12) 5
  • Monitor for urinary tract infections 9

Gastrointestinal effects 5:

  • Increased risk of diarrhea (RR 1.50), likely related to SGLT1 inhibition in the intestine 5

Monitoring Recommendations

Baseline assessment:

  • eGFR and electrolytes 10
  • HbA1c 5
  • Blood pressure and volume status 9
  • Screen for risk factors for DKA 5

Ongoing monitoring:

  • Renal function periodically, especially when eGFR approaches 25 mL/min/1.73 m² 10
  • Signs and symptoms of DKA, even with normal blood glucose (euglycemic DKA) 9
  • Volume status and blood pressure 9
  • Genital and urinary tract infection symptoms 9

Clinical Efficacy

Cardiovascular outcomes 11, 12:

  • Reduces total MACE (HR 0.77) with independent reductions in myocardial infarction (HR 0.68) and stroke (HR 0.66) 11
  • This ischaemic benefit on both MI and stroke has not been observed with selective SGLT2 inhibitors and may be related to combined SGLT1/2 inhibition 11
  • Reduces heart failure hospitalizations and urgent visits 12

Glycemic control in type 1 diabetes 5, 6:

  • Reduces HbA1c by 0.34% 5
  • Increases time in range by 9.73% 5
  • Reduces fasting plasma glucose by 16.98 mg/dL and 2-hour postprandial glucose by 39.2 mg/dL 5

Non-glycemic benefits 5:

  • Body weight reduction: 3.54% 5
  • Systolic blood pressure reduction: 3.85 mm Hg 5
  • Reduces albuminuria (albumin:creatinine ratio -14.57 mg/g) 5
  • Reduces total, basal, and bolus insulin requirements by approximately 8-9% 5

Common Pitfalls to Avoid

  1. Failing to adjust basal insulin: Always reduce basal insulin by ~20% when initiating in insulin-treated patients to minimize DKA risk 9

  2. Ignoring euglycemic DKA: Educate patients that DKA can occur even with normal blood glucose levels; maintain high clinical suspicion 8, 2

  3. Discontinuing at low eGFR: Continue therapy even when eGFR falls below 20 mL/min/1.73 m² for cardiovascular and renal protection 7

  4. Not considering perioperative risk: Discontinue 3 days before surgery to prevent ketoacidosis 9

  5. Inappropriate patient selection for type 1 diabetes: Only use in overweight/obese patients (BMI ≥27 kg/m²) with type 1 diabetes who have failed optimal insulin therapy 1

References

4
Research

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.

Expert opinion on investigational drugs, 2015

12
Research

A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor-in the Treatment of Heart Failure.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2024

Related Questions

What is the appropriate apixaban (Eliquis) dose for a patient with an estimated glomerular filtration rate (eGFR) less than 15 mL/min?
What are the indications, dosing, contraindications, and monitoring recommendations for canagliflozin in adults with type 2 diabetes mellitus?
Can I start celecoxib (Celebrex) for osteoarthritis in a patient with an estimated glomerular filtration rate of 65 mL/min?
How should a patient with chronic kidney disease stage 3b (estimated glomerular filtration rate 32 mL/min/1.73 m²) be managed?
What is the next best step in managing a 72-year-old man with type 2 diabetes, hypertension, chronic kidney disease (estimated glomerular filtration rate 42 mL/min/1.73 m²), on insulin glargine (Lantus) 34 U in the morning and 24 U in the evening, whose HbA1c increased from 8.1% to 8.8% and who cannot afford semaglutide (Ozempic) or dapagliflozin (Farxiga)?
For post‑exposure prophylaxis after a needle‑stick injury, is it necessary to use the fixed‑dose tablet containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg, and dolutegravir 50 mg, or can a regimen of bictegravir 50 mg plus emtricitabine 200 mg plus tenofovir alafenamide 25 mg be used?
In type 1 diabetes, which of the following is true: (1) insulin is required for all patients at stage 3 disease; (2) the recommended starting basal‑to‑bolus insulin ratio for a newly diagnosed insulin‑naïve patient is 50:50; (3) teplizumab (generic) is FDA‑approved to delay progression from stage 2 to stage 3 in patients aged 8 years and older; and (4) metformin is a reasonable adjunct therapy for a stage 3 patient experiencing frequent hypoglycemia despite optimal education and disease management?
Is intravenous cefuroxime an appropriate treatment for typhoid fever?
What dose of oral micronized progesterone should a healthy adult woman take to delay her period?
If a healthcare worker has a negative HIV test performed within 72 hours after a needle‑stick injury with no visible blood, should post‑exposure prophylaxis (PEP) still be initiated?
What admission orders should be placed for a patient with sepsis likely secondary to acute cholecystitis, viral hepatitis, or hepatic abscess?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.